Tagged with

LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…

Greece Angelini Pharma’s Gabriele Jannis draws on his experience in both Russia and Romania to highlight some of the key challenges for European mid-caps like Angelini in Greece, the importance of CEE countries in the company’s internationalisation efforts, and his hopes for future reform that increases the level of certainty in…

UAE 16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses the particularities of the region, and the partnerships and initiatives Gilead is actively pursuing with local stakeholders.   We have…

Belgium Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach to oncology with a focus on hard-to-treat cancers, as well as its focus on patient centricity   In oncology, we…

Belgium Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11 years in position, and highlights some of the key issues on her agenda as pharma.be’s SME subgroup chair.   The…

UAE PhRMA MEA’s Samir Khalil highlights some of the key trends at play across the Middle East and Africa’s dynamic and fast-changing pharmaceutical ecosystem, including several wide-ranging national health transformation plans, the move towards health technology assessment (HTA), and the importance of maintaining robust intellectual property (IP) protection.   We can…

China Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path…

Australia After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally significant moment for the company. New CEO Paul MacKenzie continues to pursue further growth for Australia’s largest biopharma company, investing…

India Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and Ferring’s maternal health agreement and Ipca Laboratories and Sun Pharma’s quality issues.   Zydus Lifesciences reports smallest profit in 14…

UAE Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, discusses the park’s key milestones and plans for the future, the positive changes in the UAE’s regulatory landscape since COVID, and his excitement about digital health trends and technologies.   At Dubai Science Park, we are proud to play a…

UAE AHK UAE CEO Oliver Oehms gives an overview of German healthcare investment in the Emirates, how the Chamber assists German firms in adjusting to the rapid pace of reform in the UAE, and his hopes for the future of German-Emirati economic cooperation more broadly.   We are confident that the…

Belgium Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes in his 2021 book ‘Human Scale: A Plea for Imperfection’ (‘Mensenmaat: Een Pleidooi Voor Imperfectie’ in Dutch), including why innovation…